Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

14.01 +0.12 (+0.86%)
Streaming Delayed Price Updated: 11:39 AM EDT, Aug 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pacira Pharm Inc

< Previous 1 2 3 4 Next >
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Where Pacira BioSciences Stands With Analysts
Via Benzinga
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Expert Ratings For Pacira BioSciences
Via Benzinga
NASDAQ:PCRX: good value for what you're paying.
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals. 
Via Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Via Benzinga
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Analyst Ratings For Pacira BioSciences
Via Benzinga
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Via Benzinga
Navigating 4 Analyst Ratings For Pacira BioSciences
Via Benzinga
PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Preview: Pacira BioSciences's Earnings
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
NASDAQ:PCRX is an undervalued gem with solid fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals. 
Via Chartmill
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
Via Benzinga
Earnings Preview: Pacira BioSciences
Via Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
Investors should take notice ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.